[1] |
FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong.
Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184.
|
[2] |
LI Yingfen, HAN Lei.
Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
|
[3] |
SHI Xiangfen, SUN Zhiyong, ZHANG Xufeng, LU Xiaojing, DU Shuzhang, ZHANG Xiaojian.
Whole process management of narcotic drugs and psychotropic drugs based on intelligent information management system
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 899-903.
|
[4] |
HUO Yanfei, TIAN Yuejie, XU Lili, XIE Yanjun, CHANG Hong, SUN Chunxiao, LI Xia.
535 reports of new and serious adverse drug reactions caused by preparations of lappaconitine hydrobromide
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 921-926.
|
[5] |
HUANG Cuili, GAO Ao, WANG Jiaxi, GUO Haili, XU Xiaohan, CHENG Yinchu, GUO Daihong.
Automatic monitoring and assessment of antibiotics-related thrombocytopenia
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(7): 807-811.
|
[6] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[7] |
WANG Yu, HUANG Jingyi, HOU Lixin, LI Shuang, CUI Yongkang, HUANG Lanwei.
Humoral immune characteristics of peripheral blood of CAP patients with antibiotic-associated DILI
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 132-135.
|
[8] |
YIN Jinjun, WANG Shuwei, SHAO Jiangchao, WANG Bing.
Drug use evaluation of bevacizumab injection based on weighted TOPSIS method
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1421-1426.
|
[9] |
LIU Bin, SHAO Meiling, CAI Yiran, MA Fengyi, LAN Hong.
Applicability of PDCA cycle in standardization of outpatient prescriptions
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(9): 1035-1039.
|
[10] |
WEI Hongtao, SHEN Su, LI Dandan, LIAO Yin.
Pareto chart analysis of 705 problematic prescriptions in neurology
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 900-903.
|
[11] |
MA Bingbing, ZHANG Xiaomeng, ZHANG Bing, LIN Zhijian, LYU Jintao.
Consideration of rational use of traditional Chinese medicine and pharmaceutical services for the elderly based on literature analysis
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 595-599.
|
[12] |
LI Xiaofei, CHENG Rong, WU Xuemei, LIU Zhi.
Safety of terlipressin for injection based on electronic medical records
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 654-656.
|
[13] |
CHEN Fangfang, ZHANG Hongxu.
Pharmacy practice during the treatment of primary central nervous system lymphoma with high dose methotrexate
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 446-449.
|
[14] |
JIN Haobin, ZHENG Lei, YANG Jing, GUAN Yuyao, ZHANG Xiaoli.
Adverse reactions of skin drugs and concomitant liver and kidney dysfunction in inpatients
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(3): 310-312.
|
[15] |
LYU Juan, GUO Weiyan, WANG Yuanji, LI Yamei, WANG Yingli, DUAN Shiwan.
115 cases of drug-related adverse reactions in the liver
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(2): 200-204.
|